TK-216 is a derivative of the YK-4-279 inhibitor developed for EWS-FLI1 in Ewing’s sarcoma that is currently under evaluation in a phase II clinical trial (NCT02657005, [175]). Here, EWSR1 is linked to Ewing sarcoma.